-An Interview with Onelin Capital

Life Science Nation (LSN) is pleased to announce that Onelin Capital Corporation will be a Title Sponsor of the upcoming Digital RESI Conference, taking place September 14-16. Onelin Capital, a multi-billion-dollar global conglomerate, is actively seeking life science startups interested in investments and business opportunities in the Asia market. In this interview, Judy Lee, the General Manager of Onelin Capital, will share how Onelin helped its portfolio companies to grow, what kinds of companies Onelin is seeking for future collaboration, and how Onelin is participating in the upcoming RESI.

Candice He (CH): Could you briefly introduce Onelin Capital and its mandate for early-stage life science investments?

Judy Lee (JL): Thank you, Candice. A bit about us, we are a family office backed by a 30+ year real estate global conglomerate with offices in Silicon Valley, Seattle, and Asia. We are active tech investors, meaning that our investments need to be tech-enabled, but tend to be more long-term focused. We invest across various asset classes, including direct investments into early-stage companies from Seed to Series A. Currently, we have close to 30 companies within our portfolio that are direct investments. We also participate in funds, secondaries, SPVs, etc.

For early-stage life science investments, generally, we are interested in companies that are in the analytics, diagnostics, and early prevention space as they tend to be more healthtech-related. However, if the company has a strategic value for us (meaning has an interest in going to Asia), we are still interested in the partnership/investment side.

CH: Could you please share an example or two of the life sciences companies that Onelin Capital has invested in so that our readers can know more about what kinds of companies Onelin is looking for?

JL: Of course! Our venture investment arm is Constellar Ventures. Through Constellar Ventures, we have invested in several healthtech/life sciences companies, including BioTrillion and Patchd Medical.

BioTrillion is developing a mobile health technology platform called BioEngine4D™ to digitally detect drugs and diseases by measuring data from life, analyzing it through computational advancements in machine vision and artificial intelligence, and applying it back for life. Its mission is to enable smart device technology to empower ordinary consumers with extraordinary health abilities.

Patchd Medical leverages deep learning and off-the-shelf wearables to predict the onset of sepsis in high-risk patients who have been discharged from the hospital. Its early studies have shown it can predict sepsis 8 hours earlier, and more accurately, than existing standards of care.

Both companies are healthtech-related and are much needed in the future of healthcare, especially during Covid-19. Both seek to focus on early detection, diagnostics, and remote monitoring.

CH: I noticed both companies applied to the RESI Innovation Challenge for the first time. Does Onelin always help portfolio companies to connect with useful resources and platforms like RESI? In addition to the investments, how does Onelin help portfolio companies to grow?

JL: Every single one of our investments is quite important to us. We are a family office, and our investments become part of this family. We are always open to lending a helping hand to our portfolio companies, including but not limited to connecting our portfolio companies to useful resources, introducing them to our later-stage investors, providing insights if we are able, and aligning them with strategic partners from a business expansion and development perspective. After all, we are an investor, and we want to see them succeed.

CH: As the RESI Title Sponsor, Onelin Capital is selecting 20 companies to join Onelin PitchBuzz FREE of charge. For the readers who are interested in applying, could you tell them what you look for in potential portfolio companies?

JL: Onelin Capital is looking for all life sciences-related companies who are seeking partnerships in the Asia market to work with, and tech-enabled startups for investments. If you are not selected for our PitchBuzz this time, don’t worry! We still want to get in touch with you and explore opportunities working together. Please don’t hesitate to reach out to us at onelinsv@onelincapital.com.

CH: Thank you very much for the interview, Judy.

For our readers who want to know more about Onelin Capital, RSVP for the live investor panel discussion that will be moderated by Judy, at 8 PM EST, September 10. The full panel lineup is as below. Please also check out Onelin’s website at https://www.onelincapital.com/

Moderator:

Judy Lee
General Manager
Onelin Capital

Judy is a veteran in the investment world with 15+ years of both public and private equities experience.  Coupled with years of global marketing experience, Judy is energetic and widely regarded as a growth catalyst with contagious passion. Judy currently serves as Onelin Capital Principal & General Manager, overseeing the entire family office’s operation as well as fund investments.

Judy’s LinkedIn: https://www.linkedin.com/in/thejudylee/

Panelists:

Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation
Daiichi Sankyo

Dr. Weiyong Sun is currently Senior Director, Searching and Evaluation, Global Business Development at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Immunology Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

Yao Li Ho
Senior Director of Business Development
LYFE Capital

Yao Ho is a Senior Director of Business Development at LYFE Capital. Previously, he was a part of Yangtze River Pharmaceutical Group, where he was a BD Manager. At Yangtze River Pharmaceutical Group, he was part of a team that would help the parent organization source, evaluate, coordinate due diligence and negotiate with potential international partners for pharmaceuticals, biologics and medical devices. Yao has also worked at various diagnostics, nanotechnology and digital health startups where he started as an R&D Engineer and was a member of the founding team at other companies. Yao is an MBA graduate from Tsinghua University in partnership with MIT and Bachelor’s in Biomedical Engineering from UC-Irvine with a specialization in bio-photonics and research in microfluidics.

Haolin Sung
Managing Partner
Chaperone Investment

Haolin Sung is the founder and the managing partner at Chaperone Investment, a Taiwan based VC fund focusing on angel and early stage investment in healthcare and biotech sector. He has 10+ years of experience in this field and serves as a board director for several companies including Panlabs, MountainVet, and was the board director at Pharmigene. Mr. Sung also serves in critical roles at several of the Chaperone portfolio companies including Celtech and Caliway to assist these companies in funding and business development/ licensing activities. Prior to Chaperone Investment, Mr. Sung was the director of the direct investment department for Diamond Biofund, the largest Biotech VC in Taiwan and the deputy director of Microbio Biotech Shanghai. He also worked for First Capital Management as a healthcare/biotech industry analyst. Mr. Sung earned his EMBA at Columbia University and London business school and has a B.S. in Biochemistry from Dong Hwa University.

Haruhiko Sugino
Director, Global Business Development
Otsuka Pharmaceuticals

Currently on an expatriate assignment from Japan, Haru Sugino is leading the global scouting activities for Otsuka Pharmaceutical Co., Ltd working closely with Otsuka’s US and EU BD affiliates. Haru is a part of Otsuka’s evaluation and negotiation team, charged with identifying, evaluating, and negotiating transactions to in-license new innovative compounds that address unmet medical needs in CNS/neuro and renal diseases for both global development or for regional development in Japan and Asia. Haru has been with Otsuka for 22 years in various roles, including sales, pre-clinical drug discovery, clinical R&D, commercial, and business development. Haru has a PhD for neuropharmacology, and moved to business development in 2016 after successfully launching a drug in US on which he worked for 10 years from pre-clinical discovery through to commercialization.

By Joey Wong, Investor Research Analyst, LSN

With only one week left, Digital RESI September 2020 is right around the corner! We are very excited to announce the live panel schedule for the conference.

All panels at Digital RESI September will be live-streamed. There will be two live panel sessions each day, starting as early as next week and will continue through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.

It is worth noting that Global Investment and Partnership Panel, sponsored by Onelin Capital, is open to the public (no RESI registration required). Interested readers are welcome to RSVP here and participate in this panel.

Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more. If you haven’t already, register here for RESI September 2020 to participate in these live panels!

Below is the schedule for next week’s live panel sessions:

 

Corporate VC Panel – “The Corporate Landscape Morphed & New Opportunities Abound” Date & Time: Tuesday, September 8, 10:00 – 10:50 am EST Andy Merken (Moderator), Partner and Co-Chair, Life Sciences, Burns & Levinson Lana Ghanem, Managing Director, Hikma Ventures Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund Tom Gibbs, Director, Debiopharm Innovation Fund

Medtech Strategics Panel – “Large Medical Device Firms Seeking External Innovation” Date & Time: Tuesday, September 8, 12:00 – 12:50 pm EST Geoff Dacosta (Moderator), Director of Business Development and Licensing, Medtronic Christina Salys, Director of New Business development, Intuitive Surgical David Uffer, Senior Partner, Alira Ventures Rupert Winckler, Head of EMEA New Business Development, Olympus Corporation

Health System Partners Panel – “Care Providers and Payers Seek New Technologies” Date & Time: Wednesday, September 9, 12:00 – 12:50 pm EST Cyrll Philip, Principal, Providence Ventures Linda Maxwell, Director, Biomedical Zone Mayank Taneja, Director of Venture Investments, OSF Healthcare Ventures Rajesh Aggarwal, Executive Vice President, Jefferson Strategic Ventures

Seed Funds Panel – “Investing in Emerging Science to Pursue High Rewards” Date & Time: Wednesday, September 9, 2:00 – 2:50 pm EST Gary Gershony (Moderator), Life Science Angels Anya Roy, Head of Illumina Accelerator Cambridge, Illumina Accelerator Jun Deng, Investment Partner, Joyance Partners Nancy Kaufman, CEO, Beacon Capital Prathna Ramesh, Executive Director, Maple Leaf Angels

Oncology Innovation Panel – “The Search for New Approaches to Diagnosing & Treating Cancer” Date & Time: Thursday, September 10, 12:00 – 12:50 pm EST Steve Yoder (Moderator), Vice President of Business Development, Taiho Oncology Anthony Bajoras, Managing Director, Cancer Fund Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy Duncan Young, Director of Search and Evaluation Oncology, Business Development & Licensing, AstraZeneca Mark Krul, Partner, Aglala Oncology Fund

Global Investment and Partnership Panel – “Asia Firms Looking to Build Global Partnerships” Date & Time: Thursday, September 10, 8:00 – 8:50 pm EST (Sponsored by Onelin Capital, Open to the public) Judy Lee (Moderator), General Manager, Onelin Capital Haolin Sung, Managing Partner, Chaperone Investment Haruhiko Sugino, Director of Global Business Development, Otsuka Pharmaceuticals Weiyong Sun, Senior Director of Specialty Medicine Search & Evaluation, Daichi Sankyo Yao Li Ho, Senior Director of Business Development, LYFE Capital

Impact Investors Panel – “Life Science Investors Looking for More Than Financial Returns” Date & Time: Friday, September 11, 12:00 – 12:50 pm EST Lore Gruenbaum (Moderator), Vice President of Therapy Acceleration Program, Leukemia & Lymphoma Society Chris Penland, Vice President of BioPharma Programs, Cystic Fibrosis Foundation Kuldip Dave, Vice President of Research, ALS Association Michael Cole, Founder and General Partner, Global Neurohealth Ventures Paul Larkin, Manager of Research Innovation, Crohn’s and Colitis Foundation

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

The Small Business Education and Entrepreneurial Development (SEED) Group at the National Institutes of Health (NIH) is leading a panel at RESI September on the product development pipeline. SEED is advancing the cause of scientific innovation in healthcare through collaborating with the buyers and sellers in life science to enhance relationships, products, and technology. Fundraising CEOs, strategic partners, and investors can take advantage of the opportunity to learn from the SEED team. Read below to learn more about the panel and click here to register for Digital RESI September.

NIH is SEEDing the Product Development Pipeline 

Small Business Education and Entrepreneurial Development (SEED) Group, Changing the Game for Life Science Innovators

SEED supports the NIH innovator community in their efforts to validate the potential health impacts of promising scientific discoveries and advance them into healthcare products that improve patient care and enhance health. Developing products across the biomedical spectrum requires NIH’s collaboration with universities and research institutions, small businesses, trade associations and societies, angel investors, venture capitalists, and strategic partners. SEED leads initiatives that develop these relationships and build opportunities for NIH innovators to further their product development efforts.

Matthew McMahon, PhD, Director, SEED, NIH

Matt leads the SEED Office to accelerate NIH-funded biomedical innovations from bench to bedside. SEED supports a comprehensive translational research ecosystem that includes a national network of academic proof-of-concept centers and a small business program that invests over $1 billion annually in a portfolio of more than 1500 life science companies. SEED also provides technical and entrepreneurial advisory services and builds relationships with business, finance, and healthcare stakeholders to ensure these innovations will impact patients’ lives. Matt has a diverse background in academia, biomedical small business, congressional policy, and NIH program development and management. His previous experience also includes service as the principal scientist for the bionic eye company Second Sight Medical Products and as a staff member on both the United States Senate and House of Representatives committees responsible for science, technology, and innovation policy.

Stephanie Fertig, MBA, HHS Small Business Program Lead, NIH

Ms. Stephanie J. Fertig is the HHS Small Business Program Lead in SEED (Small business Education and Entrepreneurial Development) at the National Institutes of Health (NIH). She currently oversees the Health and Human Services (HHS) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which includes the NIH SBIR and STTR programs. The HHS SBIR and STTR programs are congressionally mandated set-aside programs that provide over $1.2 billion dollars per year to small business concerns. Prior to joining SEED, she managed the SBIR and STTR Programs at the National Institute of Neurological Disorders and Stroke (NINDS). During her over 15 years at NIH she has led the development and implementation of multiple programs focused on small businesses and translational research. Ms. Fertig has a Bachelor of Science degree in Chemistry with a major in Physics from the University of Virginia and a Master of Business Administration from the University of Maryland’s Robert H. Smith School of Business.

Chris Sasiela, PhD, Team Lead, Innovator Support, SEED

Dr. Sasiela has over a decade of experience providing support and consultation to academic innovators and small businesses engaged in therapeutic, device, and diagnostic development programs. As the Innovator Support Team Lead in SEED (Small business Education and Entrepreneurial Development) in the Office of Extramural Research at the National Institutes of Health, Chris coordinates the activities of a team of seasoned professionals with experience in product and business strategy, business development, fundraising, partnerships, reimbursement, and regulatory affairs. Chris is passionate about enabling NIH’s innovator community to progress their discoveries as far as science and human biology permit. Starting her career as a researcher, Chris worked in basic research at the University of Southern California and the University of Maryland, and in drug discovery, development, and improvement groups at Baxter, the Department of the Army, and the National Cancer Institute. Chris transitioned from a research to a regulatory career path via an Interagency Oncology Taskforce Fellowship at the US Food and Drug Administration. Continuing her regulatory career path at Social & Scientific Systems, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute, Chris deepened her experience working with product development researchers understand, develop, and execute regulatory plans to get their innovative technologies from ideas to first-in-human and beyond. She regularly conducts project-focused consultations, delivers educational seminars, and develops regulatory resources for internal and external audiences. Dr. Sasiela earned a bachelor’s degree in chemistry from Whittier College, a Ph.D. in Pharmaceutical Sciences from the University of Maryland, School of Pharmacy, and has maintained Regulatory Affairs Certification status from the Regulatory Affairs Professional Society since 2011.

John Sullivan, MBA, Entrepreneur-in-Residence, SEED

John Sullivan has been a leader in healthcare technology innovation throughout his career, with extensive experience in operating, investing in, developing and acquiring market-leading businesses. Prior to the NIH, John worked with healthcare leaders such as Cardinal Health (VP, Strategy and Business Development) and Boston Scientific. He was a Partner with Foundation Medical Partners, a national healthcare venture capital firm with financial backing from the Cleveland Clinic. He also helped to start Molecular Staging Inc., a biotechnology tools company spun out of Yale University School of Medicine. Working with Yale University founders, he helped grow the company to over 100 employees, develop its product and service lines, and ultimately sell the company to Qiagen, a global life sciences company. He has served on the boards of directors of Semprus Biosciences (acquired, Teleflex), Coapt Systems (acquired, MicroAire), KEW Group, and Direct Flow Medical and held board observer roles at BridgePoint Medical (acquired, Boston Scientific) and Explorys (acquired, IBM). John earned a BS in Industrial Engineering degree with distinction from Stanford University and an MBA from the Stanford University Graduate School of Business.

By Joey Wong, Investor Research Analyst, LSN

Oncology research is a massive industry within healthcare, and the interest in innovation is only growing. One may worry that entrepreneurs are challenged to stand out and differentiate themselves in this space, however, funding cancer therapeutics remains one of the most attractive economic and philanthropic opportunities available in healthcare, and there are many firms that strongly or even solely focus on oncology.

The Oncology Innovation panel at the upcoming Digital RESI September Conference will feature 5 speakers actively seeking investment opportunities in this space. Panelists will discuss the latest in industry-wide changes, as well as the opportunities and challenges that both investors and companies are facing as they search for success in this rapidly advancing field.

The live panel session will happen on Thursday, September 10, 12:00 – 12:50 pm ET. For those who are unable to attend, the panel video will be available afterwards on the RESI September digital agenda. Check out our panelists below and click here to register for Digital RESI September.

This panel is moderated by Steve Yoder, Vice President, Business Development, Taiho Oncology

Dr. Yoder is an accomplished business development professional who has participated in many significant transactions; bringing more than 25 years of industry experience in business development, strategic planning and new product development, including in the areas of oncology and hematology, on top of his clinical experience.

Dr. Yoder joins Taiho Oncology from Bristol Myers Squibb, where he most recently served as head of the company’s Hematology and Cell Therapy Search & Evaluation team in Business Development. Prior to Bristol Myers Squibb, Dr. Yoder was Head of Search & Evaluation at Celgene Business Development, and held positions in business development, strategic planning, marketing and new product development while previously working at Bristol Myers Squibb and Pfizer. Dr. Yoder has worked as a consultant in life sciences at Easton Associates and Arthur D. Little and currently serves on the Board of Directors of Life Sciences Pennsylvania.

Anthony Bajoras, Managing Director, Cancer Fund

Anthony Bajoras is the Founder and Manager Director of the Cancer Impact Fund. He also serves as a BioAccel Board Member, manager of their for-profit BioAccelerator investment fund, and is a limited partner in the Arizona Founders Fund.

 

Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy

Named for the 1965 hit song by the Beach Boys, Barbara Ann Lavery has a passion for creativity. Whether she’s transforming the landscapes of Ireland, Iceland, and California into large-scale abstract paintings or finding and funding life-changing opportunities to cure cancer, Lavery is guided by an inspired sense of appreciation for innovation.

“Cell and gene therapies embrace an entirely new paradigm,” says Lavery whose years of experiences with non-profit and for-profit organizations, government agencies, and academic institutions helped build her framework of knowledge in life sciences. “Since its inception, ACGT has led the way in recognizing and advancing revolutionary new ideas that really matter.”

As Chief Program Officer, Lavery is responsible for many ACGT initiatives, including leadership of the Academic Research Program and the Biotechnology Investment Program. “This is my dream job,” says Lavery. “It combines science and research with business development and venture philanthropy in a forward-thinking, non-profit environment that’s dedicated to brilliant people who are finding creative new solutions to some of cancer’s toughest challenges. I love it!”

Mark Krul, Partner, Aglaia Oncology Funds

Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia in 2003 he was Program Director of the NDDO Research Foundation. He held several positions with NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 until 1997 Mark was Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 until 1993.

Duncan Young, Director, Search and Evaluation Oncology, BD&L, AstraZeneca

Duncan is a Experienced Business Development professional passionate about early innovation and technology, with keen interest new models of collaborative working and open innovation between academia, the charity sector and industry, and supporting and mentoring life science entrepreneurs.

Specialities: Open Innovation, Drug Discovery, Mentoring, Medical Technologies, Technology Transfer, IP Management, Technical Due Diligence and Evaluation, Networking, Agreement Negotiation, Consortia Drafting, Strategy.

By Karen Deyo, Senior Investor Research Analyst, LSN

There has been a large paradigm shift in healthcare delivery this calendar year and adapting to this digital age will require adoption of new technologies, providing a great opportunity for up-and-coming digital health companies to showcase themselves. At our upcoming Digital RESI conference taking place September 14-16, the panelists will discuss how investing in digital health has changed, which technologies are gaining the most traction, and how to approach investors in the current industry landscape.

We are happy to introduce the speakers participating on the Digital Health Investors panel!

Moderator: Robert Garber, Partner at 7wire Ventures

For over 25 years, Robert Garber has worked with early-stage healthcare and technology companies, co-managing three venture funds with $200M+AUM and holding leadership positions with three high-growth companies. Robert is currently a Partner at 7wire Ventures, where he focuses on investments in digital healthcare and technology-enabled services that empower consumers to be better stewards of their health and healthcare expenditures. 7wireVentures is an early stage, healthcare venture firm that supports entrepreneurs who focus on empowering the Connected Informed Health Consumer to create great companies and change the status quo. 7wire believes that mobile, connected platforms, the cloud, and sophisticated insights will improve the efficiency of the healthcare system and improve outcomes for all.

Evan Cohen, Associate Principal, Strategic Investing at Healthbox

Evan is part of the investment team for the DaVita Venture Fund. Previously, he led M&A and strategic payer activities at Genoa Healthcare (OptumRx division), the country’s leading behavioral health pharmacy, telepsychiatry and medication management services company. Evan joined Genoa Healthcare through the acquisition of 1DocWay, where
he managed clinic-based telepsychiatry sales. He was formerly a healthcare investment banker at Piper Jaffray, where he advised biopharmaceutical, medical device, and healthcare services companies on capital raising and M&A transactions. Evan began his career at BlackRock, where he served as a fixed income product specialist managing institutional client business totaling nearly $100B AUM. Evan resides in New York City and received his BA in Economics from Northwestern University and his MBA from Columbia Business School.

Roy Wiesner, Managing Director at aMoon Fund

Roy Wiesner is a Managing Director at aMoon Fund, Israel’s largest life sciences and healthtech VC. He focuses on early-stage investments, primarily in digital health and medical devices. Prior to joining aMoon, he was the CEO of a Cleantech incubator and seed-stage fund owned by CK Hutchison (Fortune 500 company), where he was also involved in forming a number of ventures. Roy was previously a corporate lawyer, specializing in M&A, Private Equity and VC transactions, working for international law firm Weil Gotshal in New York and Hong Kong, and as a partner for a prominent law firm in Tel Aviv. He holds an LL.B from the Hebrew University and a dual MPA from the LSE and Columbia University.

Ben Evans, Investment Director at InHealth Ventures

Netalie Nadivi, Partner at TriVentures

Netalie has 20 years of professional experience in technology start-up and global corporate environments. Netalie’s interdisciplinary and holistic background, working with start-ups from different vantage points throughout her career, contributes greatly to the evaluation and identification of investment opportunities and portfolio management.

Netalie spent over a decade at Philips in various corporate capacities including Director of Business Development and M&A. She brings with her tremendous transaction and project management experience in investments, strategic partnerships, acquisitions and post-merger integration spanning across several industries including healthcare and consumer health and wellness.

Prior to her time at Philips, Netalie gained experience in a technology start-up and an accelerator that set up companies from stage zero. In both positions, Netalie held senior multidisciplinary CEO support roles where she was responsible for the companies’ business, legal and financial affairs.

Netalie holds a M.S. in Management from Boston University and a B.A. in Legal Studies from the University of California at Berkeley.

This panel will be live-streamed on Wednesday, September 16, 2020 at 2:00 pm EDT – Make sure to register for RESI to join this and other exciting panels!

A corporate venture arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the firm’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platform technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.